Post-translational modifications: Principal regulators of bladder cancer

Zhiyuan Deng^{1

2}, Zhiwei Yan^{1

2}, Zhiyuan Chen^{3

4}

Affiliations

¹ Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China.
² Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China.
³ Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China. drchenzy@whu.edu.cn.
⁴ Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China. drchenzy@whu.edu.cn.

Review

Zhiyuan Deng et al. Mol Biol Rep. 2026.

. 2026 Feb 27;53(1):446.

doi: 10.1007/s11033-026-11584-6.

Zhiyuan Deng^{1

2}, Zhiwei Yan^{1

2}, Zhiyuan Chen^{3

4}

¹ Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China.
² Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China.
³ Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China. drchenzy@whu.edu.cn.
⁴ Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China. drchenzy@whu.edu.cn.

No abstract available

Keywords: Biomarker; Bladder cancer; Post-translational modification; Targeted therapy.

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660 - DOI
1. Dyrskjøt L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Theodorescu D (2023) Bladder cancer. Nat reviews Disease primers 9(1):58. https://doi.org/10.1038/s41572-023-00468-9 - DOI - PubMed - PMC
1. Lenis AT, Lec PM, Chamie K (2020) Bladder Cancer: A Review. JAMA 324(19):1980–1991. https://doi.org/10.1001/jama.2020.17598 - DOI - PubMed
1. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Gurski LA (2024) NCCN Guidelines^® Insights: Bladder Cancer, Version 3.2024. J Natl Compr Cancer Network: JNCCN 22(4):216–225. https://doi.org/10.6004/jnccn.2024.0024 - DOI - PubMed
1. Han J, Gu X, Li Y, Wu Q (2020) Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed pharmacotherapy = Biomedecine pharmacotherapie 129:110393. https://doi.org/10.1016/j.biopha.2020.110393 - DOI - PubMed